nebokitug

Home
Ligands
nebokitug

GtoPdb Ligand ID: 13666

Synonyms: CM-101 | CM101

Comment: Nebokitug is the INN for an anti-C-C motif chemokine ligand 24 (CCL24) monoclonal antibody (proposed INN list 131, August 2024). It is likely clinical lead CM-101 (ChemomAb Ltd.). CCL24 is a soluble cytokine that is an important regulator of inflammation and fibrosis in human diseases such as primary sclerosing cholangitis (PSC) [1], systemic sclerosis, metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). It promotes recruitment and activation of both immune cells and fibroblasts and this combined action induces over-production of extracellular matrix components that underlie fibrosis. Blocking CCL24-mediated signalling, via its receptor CCR3, with CM-101 has demonstrated therapeutic potential in preclinical PSC models [3-4].

References
1. Greenman R, Segal-Salto M, Barashi N, Hay O, Katav A, Levi O, Vaknin I, Aricha R, Aharoni S, Snir T et al.. (2023) CCL24 regulates biliary inflammation and fibrosis in primary sclerosing cholangitis. JCI Insight, 8 (12). [PMID:37345655]
2. Mor A, Friedman S, Hashmueli S, Peled A, Pinzani M, Frankel M, Safadi R. (2024) Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies. Drug Saf, 47 (9): 869-881. [PMID:38822943]
3. Mor A, Segal Salto M, Katav A, Barashi N, Edelshtein V, Manetti M, Levi Y, George J, Matucci-Cerinic M. (2019) Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis. Ann Rheum Dis, 78 (9): 1260-1268. [PMID:31129606]
4. Segal-Salto M, Barashi N, Katav A, Edelshtein V, Aharon A, Hashmueli S, George J, Maor Y, Pinzani M, Haberman D et al.. (2020) A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage. JHEP Rep, 2 (1): 100064. [PMID:32039405]

References

1. Greenman R, Segal-Salto M, Barashi N, Hay O, Katav A, Levi O, Vaknin I, Aricha R, Aharoni S, Snir T et al.. (2023)
CCL24 regulates biliary inflammation and fibrosis in primary sclerosing cholangitis.
JCI Insight, 8 (12). [PMID:37345655]

2. Mor A, Friedman S, Hashmueli S, Peled A, Pinzani M, Frankel M, Safadi R. (2024)
Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies.
Drug Saf, 47 (9): 869-881. [PMID:38822943]

3. Mor A, Segal Salto M, Katav A, Barashi N, Edelshtein V, Manetti M, Levi Y, George J, Matucci-Cerinic M. (2019)
Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis.
Ann Rheum Dis, 78 (9): 1260-1268. [PMID:31129606]

4. Segal-Salto M, Barashi N, Katav A, Edelshtein V, Aharon A, Hashmueli S, George J, Maor Y, Pinzani M, Haberman D et al.. (2020)
A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage.
JHEP Rep, 2 (1): 100064. [PMID:32039405]